The pandemic has accelerated the adoption of nearly anything that can be done remotely and telehealth has been one of the immediate beneficiaries. Ro is the digital telehealth company whose digital clinics allow patients to leverage technology for affordable access to common health services. With this latest funding, Ro has tripled its valuation from in the last fifteen months since its Series B (this round comes at a $1.5B valuation) and is on pace to do $250M in revenue this year. We caught up with CEO and Cofounder Zachariah Reitano to learn more about the company’s impressive growth, plans to double the size of its engineering team, and the latest round of funding from investors that include General Catalyst, FirstMark Capital, Torch Capital, SignalFire, TQ Ventures, Initialized Capital, 3L, BoxGroup, and The Chernin Group.
“Investors don’t like hardware, and rowing can be perceived as a niche interest. We had to respond to concerns like ‘what if Peloton copies your content,’ and manage the difficulty of effectively demo-ing our product given that it’s a large piece of hardware and COVID-19 made transporting the rowers a bigger challenge.” Learn more about how Tom Aulet of Ergatta, a connected fitness startup that offers elegantly designed in-home rowing machines with a gamification element, was able to successfully raise $5M for the company during the pandemic from investors that include Greycroft and Techstars.
Mike Edelhart of Social Starts walks us through some observations on how COVID-19 has impacted trends from a VC’s perspective.
The average time to get a drug to market, crossing FDA hurdles, is 12 years and costs in excess of $1B. And in those twelve years, there is animal testing, human trials, and dozens of other steps that a company needs to go through. TARA Biosystems has found a way to generate human tissue OUTSIDE of the body that can be used in the drug development process to test safety and effectiveness without harming animals or risking human life. CEO Misti Ushio shares some insight on the potential of in vitro biology for drug development, TARA Biosystem’s different lines of business, and recent funding round from investors that include OMX Ventures, Merieux Equity Partners, Partnership Fund for New York City, Trancos Ventures, DEFTA Partners, and Tachyon Ventures.
In 2016, Cedar CEO and Founder Florian Otto had a terrible billing experience when his then-fiancé, now wife, fainted and had to go to the emergency room. The couple found themselves dealing with a billing nightmare in the months that followed including indecipherable stacks of paper bills, statements sent to the wrong address, and even a call from a debt collector. This led Florian to found Cedar, the patient payment engagement platform to simplify medical bills and the experience for both providers and patients. He shares some insights with us on the state of medical billing, the efficacy of the platform, and the company’s recent funding round from investors that include Andreessen Horowitz, Thrive Capital, and Founders Fund.
For the majority, traditional weight loss programs don’t work long-term. The weight loss industry has been focusing on the number on the scale, but the science tells us it’s more complicated. Calibrate, backed by $5.1M Seed round led by Forerunner Ventures, addresses metabolic change to bring sustainable results for the 175M Americans that are overweight. Isabelle Kenyon shares more about the science behind weight loss and the company’s future plans.
Loneliness and isolation are heightened in the midst of the pandemic. Can robots fill a void? Expper’s founder Karén Khachikyan says the company’s robot Robin changes a kid’s perception of medical treatments, where they will no longer feel isolated, lonely, and scared. The innovator explains how his whimsical four-foot robot employs digital facial expressions to form lasting bonds with its young users.
The promise of big data and machine learning has significant ramifications for treatments in the healthcare industry. However, due to privacy concerns, innovation is often stifled. Thomas Clozel, MD, an assistant professor of oncology, saw this roadblock firsthand and cofounded Owkin – a collaborative platform that allows medical researchers to gain insights from decentralized data without breaching any privacy protocols. Clozel offers some insight into how Owkin is changing the medical research landscape powered by machine learning and algorithms.
Any parent knows that a well-rested baby is a happy baby. Nanit, the smart baby sleep monitoring connected solution, uses data science and analytics to understand an infant’s sleep patterns to optimize sleep. CEO Sarah Dorsett shares more on the company’s product pipeline and recent funding round, which brings Nanit’s total funding raised to $49.6M.
Already five regions within New York State have reopened for business, ushering in a new reality of “test, isolate, and trace.” The United States estimates it will hire close to 300,000 people to become contact tracers, identifying potential spreaders of the virus. Governor Cuomo has appointed former New York City Mayor Michael Bloomberg to head […]
The human immune system is a complex network made up of cells, proteins, and organs that protect your body. Advances in technology have allowed researchers, scientists, and physicians to understand this sophisticated system like never before. Immunai, cofounded by Noah Solomon, leverages machine learning and artificial intelligence to provide a complete profile of the immune system. The company just launched from stealth with a fresh $20M in funding. Noah shares with us how Immunnaii is building the largest database for immunology.